Published in Cancer Weekly, April 1st, 2003
Researchers at the Harvard affiliated teaching hospital, which is located in Boston, Massachusetts, have examined the effects of combining recombinant tissue plasminogen activator (rt-PA) and captopril in several in vitro assays and in vivo assays, and in cancer patients. Sulfhydryl donors such as captopril mediate the formation of antiangiogenic angiostatin, a downstream product of plasminogen activator activity. Researchers depleted study plasma of angiostatin in order to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.